<i>Stixis scandens</i>leaf extract-loading ZnO nanoparticles for porcine epidemic diarrhea virus (PEDV) treatment

✅ 全文

<i>Stixis scandens</i>叶提取物负载ZnO纳米颗粒用于猪流行性腹泻病毒(PEDV)治疗

作者 Thi Thu Huong Le; Thi Tam Than; Thi Ngọc Ha Lai; Van Phan Le 期刊 RSC Advances 发表日期 2024 卷/期/页码 Vol. 14(13) ISSN 2046-2069 DOI 10.1039/d3ra08928b 类型 原创研究 (Original Research)

📄 英文摘要 English Abstract

EN

Various nanoformulations of ZnO andStixis scandensleaf extract were successfully synthesized. The A1T nanoformulation, containing only 7.6% extract, showed an equivalent anti-PEDV activity with the extract.

📄 中文摘要 Chinese Abstract

中文
猪流行性腹泻(PED)是给畜牧业者造成巨大损失的疾病之一。由于针对该疾病的疫苗效果不佳,市场对具有有效抗猪流行性腹泻病毒(PEDV)活性的生物制品需求很大。当今最重要的趋势之一是在畜牧业中使用天然来源的活性成分。本研究旨在从已被证实具有抑制PEDV作用的锡生藤(*Stixis scandens*)提取物中开发出一种有效的抗PEDV制剂。 天然产物长期以来被广泛研究作为抗病毒剂。近年来,针对PEDV具有天然抗病毒活性的物质研究受到了极大关注。在先前的一项研究中,对多种越南药用植物进行了筛选,结果表明锡生藤叶的乙醇提取物相比其他提取物是最有效的抗PEDV制剂。开发药用植物物质的纳米制剂是治疗多种病毒疾病的潜在趋势,纳米ZnO制剂显示出巨大潜力。氧化锌(ZnO)长期以来一直被用作减少仔猪腹泻的制剂。

📋 英文结构化总结 English Structured Summary

全文整理

EN

Background:

Porcine epidemic diarrhea (PED) is one of the diseases that causes great losses for livestock farmers. Because vaccines against the disease are not very effective, there is a great demand for biological products with effective resistance to PED virus (PEDV). One of the most important trends today is the use of active ingredients from nature in animal husbandry. This study aimed to create an effective agent against PEDV from the extract of *Stixis scandens*, which has been shown to inhibit PEDV.

Natural products have long been widely studied as antiviral agents. Recently, research on substances with natural antiviral activity against PEDV has received great attention. In a previous study, many Vietnamese medicinal plants were screened and the ethanolic extract of *Stixis scandens* leaves was determined to be the most effective anti-PEDV agent compared to other extracts. Developing nanoformulations of medicinal substances from plants is a potential trend in the treatment of many virus diseases, and nano ZnO nanoformulations show much potential. Zinc oxide ZnO has long been used as an agent to reduce diarrhea in piglets.

Methods:

The aqueous (denoted as TCN) and ethanolic extracts (denoted as TCC) of *Stixis scandens* leaves were first prepared and then qualitatively analyzed for their chemical compositions. The TCN was used to synthesize ZnO nanoparticles (NPs) at various sizes from 20 to 120 nm. Subsequently, TCC was loaded on ZnO NPs to form ZnO-extract nanoformulations with an extract loading content of 5.8–7.6%.

Results:

Total polyphenols (TP) and total alkaloids (TA) in TCC were 38.51 ± 0.25 mg GAE per mg and 22.37 ± 0.41 mg AtrE per mg, respectively. TP was less loaded but more released from the nanoformulations than TA. The A1T nanoformulation, containing only 7.6% extract, had a minimum PEDV inhibitory concentration of 3.9 mg mL⁻¹, which was comparable to that of TCC. The experiments confirmed that the nanoformulations are promising for PEDV inhibition applications.

Data Summary:

- Total polyphenols in TCC: 38.51 ± 0.25 mg GAE per mg - Total alkaloids in TCC: 22.37 ± 0.41 mg AtrE per mg - Extract loading content in nanoformulations: 5.8–7.6% - Minimum PEDV inhibitory concentration of A1T nanoformulation: 3.9 mg mL⁻¹ - ZnO nanoparticle sizes: 20 to 120 nm

Conclusions:

The experiments confirmed that the nanoformulations are promising for PEDV inhibition applications. The A1T nanoformulation, containing only 7.6% extract, had a minimum PEDV inhibitory concentration comparable to that of the ethanolic extract (TCC).

Practical Significance:

The developed ZnO-extract nanoformulations offer a way to improve the effectiveness and reduce the dosage of plant extracts for PEDV treatment applications. Using nano Zn in pig diets can reduce the amount of Zn needed by up to 60% without losing the effect on the intestinal microbiota, and ZnO has been shown to exert antiviral and anti-inflammatory effects on PEDV-infected piglets. This nanoformulation approach could provide a practical biological product for controlling PEDV in livestock.

📋 中文结构化总结 Chinese Structured Summary

中文

背景:

猪流行性腹泻(PED)是给畜牧业者造成巨大损失的疾病之一。由于针对该疾病的疫苗效果不佳,市场对具有有效抗猪流行性腹泻病毒(PEDV)活性的生物制品需求很大。当今最重要的趋势之一是在畜牧业中使用天然来源的活性成分。本研究旨在从已被证实具有抑制PEDV作用的锡生藤(*Stixis scandens*)提取物中开发出一种有效的抗PEDV制剂。

天然产物长期以来被广泛研究作为抗病毒剂。近年来,针对PEDV具有天然抗病毒活性的物质研究受到了极大关注。在先前的一项研究中,对多种越南药用植物进行了筛选,结果表明锡生藤叶的乙醇提取物相比其他提取物是最有效的抗PEDV制剂。开发药用植物物质的纳米制剂是治疗多种病毒疾病的潜在趋势,纳米ZnO制剂显示出巨大潜力。氧化锌(ZnO)长期以来一直被用作减少仔猪腹泻的制剂。

方法:

首先制备锡生藤叶的水提物(标记为TCN)和乙醇提取物(标记为TCC),然后对其化学成分进行定性分析。利用TCN合成了粒径从20至120 nm不等的ZnO纳米颗粒(NPs)。随后,将TCC负载到ZnO纳米颗粒上,形成提取物负载含量为5.8–7.6%的ZnO-提取物纳米制剂。

结果:

TCC中总多酚(TP)和总生物碱(TA)含量分别为38.51 ± 0.25 mg GAE/mg和22.37 ± 0.41 mg AtrE/mg。与TA相比,TP在纳米制剂中的负载量较低但释放量更高。仅含7.6%提取物的A1T纳米制剂对PEDV的最小抑制浓度为3.9 mg mL⁻¹,与TCC相当。实验证实,该纳米制剂在PEDV抑制应用中具有良好前景。

数据摘要:

- TCC中总多酚含量:38.51 ± 0.25 mg GAE/mg - TCC中总生物碱含量:22.37 ± 0.41 mg AtrE/mg - 纳米制剂中提取物负载含量:5.8–7.6% - A1T纳米制剂对PEDV的最小抑制浓度:3.9 mg mL⁻¹ - ZnO纳米颗粒粒径:20至120 nm

结论:

实验证实,该纳米制剂在PEDV抑制应用中具有良好前景。仅含7.6%提取物的A1T纳米制剂对PEDV的最小抑制浓度与乙醇提取物(TCC)相当。

实际意义:

所开发的ZnO-提取物纳米制剂为提高植物提取物在PEDV治疗应用中的有效性并降低其用量提供了一种途径。在猪日粮中使用纳米Zn可将所需Zn用量减少多达60%,且不影响其对肠道微生物群的作用,并且ZnO已被证实对PEDV感染的仔猪具有抗病毒和抗炎作用。该纳米制剂方法可为控制畜牧业中的PEDV提供一种实用的生物制品。

📖 英文全文 English Full Text

EN

Open Access Article. Published on 14 March 2024. Downloaded on 5/31/2026 2:41:26 AM. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. RSC Advances View Article Online

PAPER Cite this: RSC Adv., 2024, 14, 8779 View Journal | View Issue

Stixis scandens leaf extract-loading ZnO nanoparticles for porcine epidemic diarrhea virus (PEDV) treatment Thi Thu Huong Le, a Thi Tam Than,b Thi Ngọc Ha Laic and Van Phan Le*c

Porcine epidemic diarrhea (PED) is one of the diseases that causes great losses for livestock farmers. Because vaccines against the disease are not very effective, there is a great demand for biological products with effective resistance to PED virus (PEDV). One of the most important trends today is the use of active ingredients from nature in animal husbandry. This study aimed to create an effective agent against PEDV from the extract of Stixis scandens, which has been shown to inhibit PEDV. The aqueous (denoted as TCN) and ethanolic extracts (denoted as TCC) of Stixis scandens leaves were first prepared and then qualitatively analyzed for their chemical compositions. The TCN was used to synthesize ZnO nanoparticles (NPs) at various sizes from 20 to 120 nm. Subsequently, TCC was loaded on ZnO NPs to form ZnO-extract nanoformulations with an extract loading content of 5.8–7.6%. Total polyphenols (TP) Received 29th December 2023 Accepted 9th March 2024

and total alkaloids (TA) in TCC were 38.51 ± 0.25 mg GAE per mg and 22.37 ± 0.41 mg AtrE per mg, respectively. TP was less loaded but more released from the nanoformulations than TA. The A1T DOI: 10.1039/d3ra08928b

nanoformulation, containing only 7.6% extract, had a minimum PEDV inhibitory concentration of 3.9 mg mL−1, which was comparable to that of TCC. The experiments confirmed that the nanoformulations are rsc.li/rsc-advances

promising for PEDV inhibition applications.

1. Introduction Porcine epidemic diarrhea (PED), caused by a virus, is one of the most important diseases in the swine industry. PEDV is a positive-sense single-stranded RNA virus, belonging to the Coronavirinae family.1 This family of viruses causes a variety of diseases in mammals and birds, from enteritis in cows and pigs to upper respiratory disease in chickens and fatal human respiratory infections, such as severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome (MERS) and Covid-19 (SARS-CoV-2).2 PEDV can cause severe watery diarrhea and subsequent dehydration in pigs of all ages and high mortality in 7–10 day-old piglets. Although several vaccines have been used to prevent PEDV such as live attenuated vaccines, recombinant vector vaccines, DNA vaccines, and subunit vaccines. it is still not possible to prevent outbreaks of PEDs, due to these types of vaccines which are generally not very effective.3 Therefore, there is a great need for antiviral biological products for disease prevention and treatment. Some previous studies have discovered many compounds with anti-PEDV properties such as 2-deoxy-D-glucose,4 glycyrrhizin,5 and

Faculty of Natural Resources and Environment, Vietnam National University of Agriculture, Trau Quy, Gia Lam, Hanoi, Vietnam. E-mail: lethithuhuong@vnua.edu.vn b Institute of Veterinary Science and Technology, Trau Quy, Gia Lam, Hanoi, Vietnam

c

College of Veterinary Medicine, Vietnam National University of Agriculture, Hanoi, Vietnam. E-mail: letranphan@vnua.edu.vn © 2024 The Author(s). Published by the Royal Society of Chemistry

surfactin.6 However, there is currently no effective commercial drug to control PEDV infection. Natural products have long been widely studied as antiviral agents.7 Recently, research on substances with natural antiviral activity against PEDV has received great attention. For example, tomatidine, a steroid alkaloid extracted from tomato peels and leaves, showed signicant inhibition of PEDV replication in Vero and IPEC-J2 cells in vitro. It was found that the mechanism of inhibition of PEDV by tomatidine is that tomatidine inhibits PEDV replication mainly through the 3CL protease. In addition, tomatidine has in vitro antiviral activity against transmissible gastroenteritis virus (TGEV), porcine reproductive and respiratory syndrome virus (PRRSV), encephalomyocarditis virus (EMCV), and seneca virus A (SVA).2 In another study, an aqueous extract of Moringa (M. oleifera) leaves was able to inhibit PEDV infection during its replication phase in vitro. In addition, M. oleifera extract inhibits PEDV infection by preventing oxidative stress and apoptosis caused by PEDV infection.8 Aloe extract at a concentration of 16 mg mL−1 could inhibit the replication of PEDV in vitro and cause inhibition at the late stage of the virus's life cycle. Aloe vera extract at a concentration of 100 mg per kg body weight, which is relatively safe in mice, can reduce viral load and pathological changes in the intestinal tract of pigs and protect piglets from experimental toxicity with the PEDV GDS01 strain.9 In a previous study, many Vietnamese medicinal plants were screened and the ethanolic extract of Stixis scandens leaves was determined to be the most effective anti-PEDV agent compared to other extracts.10

Open Access Article. Published on 14 March 2024. Downloaded on 5/31/2026 2:41:26 AM. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

RSC Advances Stixis scandens, also known as Stixis elongata Pierre, belongs to the Capparidaceae family and is used by people to treat tendon and bone pain, and rheumatism, and the leaves are used to treat eye diseases.11 As far as we know, the chemical composition of this plant has been studied quite limited. A 2023 publication showed two new N-containing glycoside compounds in the composition of Stixis scandens leaves.12 A similar plant, Stixis suaveolens Roxb, in the same family, has been studied for some of its chemical components.13 From the Stixis suaveolens Roxb plant, Vietnamese scientists have developed a method to extract the compound Cappariloside A.14 The compound which belongs to the alkaloid group has been shown to have the ability to ght many viruses, including inuenza viruses H1N1 and H3N2, PIV3, and ADV.15 Although plant extracts can inhibit the growth of viruses, their effectiveness depends on the concentration of the active compounds. Since these compounds also have anti-nutritional properties, the level of plant extracts included in the animal's diet is limited because otherwise feed intake or nutrient digestibility may be affected or decreased.16 In addition, in the above in vivo test, although aloe vera extract showed resistance to PEDV, at high concentrations, the extract could increase blood viscosity and cause mild diarrhea in piglets.9 Therefore, it is essential to improve the effectiveness and reduce the dosage of plant extracts for PEDV treatment applications. Developing nanoformulations of medicinal substances from plants is a potential trend in the treatment of many virus diseases.17 There are various nanoformulations used as antiviral drug delivery vehicles such as lipid nanosystems, polymer nanosystems, lipid–polymer nanosystems, carbon nanocomposites, metal nano/inorganic metal oxides.,18 among which nano ZnO nanoformulations show much potential. Zinc oxide ZnO has long been used as an agent to reduce diarrhea in piglets. In a study on the effects of ZnO on PEDVinfected piglets, the results showed that using ZnO at a dose of 100 mg per kg body could improve growth performance, intestinal redox status, and intestinal morphology state, function and reduce diarrhea in PEDV-infected piglets. ZnO can exert antiviral and anti-inammatory effects on PEDV-infected piglets by regulating neutrophil degranulation. However, this study used non-nano-sized ZnO particles.19 Nutritionally, nanosized Zn supplements have higher bioavailability in animals than micro-sized Zn, allowing more interactions to occur in the intestine and better absorption.20 Using nano Zn in pig diets can reduce the amount of Zn needed by up to 60% without losing the effect on the intestinal microbiota.21 ZnO nanoparticles are able to inhibit many viruses such as H1N1,22,23 HSV-1 (ZnO-PEG nanoparticles at a concentration of 200 mg mL−1 reduce the virus titer by 2.5 log 10 TCID50, and reduce by 92% DNA copy of this virus)24 or ZnO nanoparticles synthesized using Plumbago indica L. plant extract with CC50 (50% cell cytotoxic concentration) and IC50 equal to 43.96 ± 1.39 and 23.17 ± 2.29 mg mL−1.25 In 2023, chiral ZnO nanoparticles were also investigated for their antiviral activity.26 In the study, L-ZnO nanoparticles showed higher antiviral activity against porcine reproductive and respiratory syndrome virus (PRRSV) than D-ZnO and DLZnO. Recently, many publications have shown the potential of

Paper nano ZnO in inhibiting SARS-CoV-2. For example, PEGylated ZnO nanoparticles have IC50 = 526 ng mL−1; CC50/IC50 # 1.27 ZnO nanoparticles synthesized with different phenolics were predicted in silico models to be able to inhibit SARS-CoV-2.28 In a review study published in 2022, the authors presented the antiviral mechanisms of ZnO nanoparticles and also conrmed the supply of Zn, an essential trace element, especially in the form of nano helps support the prevention and treatment of Covid-19.29 ZnO nanoparticles (30–60 nm) inactivated the Delta and Omicron SARS-CoV-2 with a stronger effect than larger ZnO nanoparticles.30 For PEDV, we only found one summary report showing that ZnO can inactivate PEDV, but does not destroy this virus particle.31 In this study, ethanolic and aqueous extracts were prepared from the leaves of Stixis scandens, and their chemical compositions were determined. Moreover, it is the rst time that both aqueous and ethanolic extracts of Stixis scandens leaves were used for the synthesis of ZnO nanoformulations for the treatment of PEDV.

2.1. Materials The leaves of Stixis scandens were collected in Vu Quang, Ha Tinh, Vietnam and the scientic name of the plant was identied at the Vietnam National Museum of Nature. The leaves were washed and dried at 40 °C for 24 h, then nely ground and stored in an airtight container. The chemicals used include: food alcohol (96°), distilled water, atropine sulfate standard, bromocresol green, gallic acid standard, Folin-Ciocâlteu reagent, Zn(CH3COO)2$2H2O, and other commonly used chemicals were of analytical grade, and were used directly without rening. 2.2. Research methods 2.2.1. Preparation of extract of leaves of Stixis scandens. 100 g of Stixis scandens leaf powder was soaked in 2 L of distilled water or 2 L of 96° ethanol for 48 h combined with 3 times of ultrasonic vibration every 24 h at room temperature, 30 min apart, 15 min each time. The extract was then ltered through a cotton stopper followed by Whatman® lter paper (no. 1) before use in qualitative determination. To determine the total polyphenols, total alkaloids, and antiviral activities of the extracts, they were concentrated using a rotary evaporator at low temperature (40 °C) and reduced pressure, and then lyophilized to constant mass and stored in an airtight container at 4 °C. The aqueous and alcohol extracts of the leaves are designated as TCN and TCC, respectively. 2.2.2. Qualitative determination of the chemical composition of Stixis scandens. The phytochemical composition of the extracts was determined by common methods with some modications.32,33 Phenolic compounds were determined by the FeCl3 test. Mix 1.0 mL of TCN or TCC and 1.0 mL of 0.1 M FeCl3 solution. The change in color of the solution indicates the presence of polyphenol compounds. Saponins were tested by foaming test and Fehling test. 0.5 mL of TCC or TCN was diluted with 2.0 mL distilled water

© 2024 The Author(s). Published by the Royal Society of Chemistry View Article Online

Open Access Article. Published on 14 March 2024. Downloaded on 5/31/2026 2:41:26 AM. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

Paper and stirred vigorously in a test tube. The presence of saponins is recognized by the stable foams that are formed. Fehling reagent was prepared by mixing 1.0 mL of 1 M CuSO4; 1.0 mL 2 M NaOH and 1.0 mL 10% sodium-potassium tartrate solution. Fehling reagent was added to 1.0 mL of TCC or TCN and the mixture was then heated. The presence of saponins was further conrmed by a red precipitate. Alkaloids were detected using the Dragendorff reagent. Dragendorff reagent was synthesized by reacting 5% excess KI solution and Bi(NO3)3 solution in an acidic medium. TCN and TCC were dotted on silica gel plates, which were dipped in Dragendorff reagent solution, and alkaloids were identied by the orange color appearing at the extraction site. For the determination of glycosides, 1.0 mL of acetic acid and 1.0 mL of chloroform were mixed with 1.0 mL of TCN or TCC. The mixture was placed in a beaker of ice before adding concentrated H2SO4. The appearance of the green color of the solution indicates the presence of glycosides in the extract. Trim–Hill reagent (acetic acid – 0.2% CuSO4 – concentrated HCl, 10 : 1 : 0.5) was used for the determination of iridoids. 0.5 mL of TCC or TCN was added to 4 mL of Trim–Hill agent and mixed well. The blue color shows the presence of iridoids. The presence of avonoids in the extract was used by the reaction of TCC or TCN with a mixture of 1 mL of 5% NaNO2, 1 mL of 10% Al(NO3)3, and 10 mL of 4% NaOH solution. The yellow color conrms the presence of avonoids. 2.2.3. Quantication of total polyphenols (TP) and total alkaloids (TA) in extracts. The TP and TA in the extracts were analyzed following a published report.34 2.2.3.1. Determination of TP based on gallic acid standard substance. Gallic acid was diluted in water to a stock solution of 200 mg mL−1 and prepared into a standard series of concentrations of 20, 40, 60, 80, and 100 mg mL−1. Folin-Ciocâlteu reagent was diluted 10 times. Take 0.5 mL of gallic acid standard solution, add 2.5 mL of diluted Folin-Ciocâlteu reagent, and add 2 mL of 7.5% Na2CO3 solution. The solution was allowed to stand for 2 h, and then the UV-Vis spectra of the standard series were recorded to determine the maximum absorption wavelength and to establish the gallic acid standard curve. The TP content in TCC and TCN was determined in a similar way to the standard series measurement, where 0.5 mL of the standard solution was replaced by 0.5 mL of TCC or TCN solution (TCC: 1.2 mg mL−1 ethanol, TCN: 1 mg mL−1 water). The TP content in the extract was then calculated from the calibration curve and expressed as gallic acid equivalent (GAE). 2.2.3.2. Determination of TA based on atropine standard. Accurately weigh 10.8 mg of atropine sulfate ((C17H24NO3)2SO4$H2O M = 694.8 g mol−1), dissolve in 50 mL distilled water to obtain atropine stock standard solution (C17H23NO3 M = 289 g mol−1) 180 mg mL−1. Atropine standard series with concentrations of 5, 9, 18, 27, 36 mg mL−1 were prepared from the atropine standard solution. Prepare a solution of bromocresol green with a concentration of 1 mmol l−1 in an alkaline environment (NaOH). Prepare 0.1 M NaH2PO4 buffer (pH = 4.7). Take 3 mL of atropine standard solution, add 5 mL of bromocresol green solution, 5 mL of phosphate buffer, and 5 mL of chloroform to the separatory

© 2024 The Author(s). Published by the Royal Society of Chemistry

RSC Advances funnel, shake vigorously for 2 min, and take the soluble yellow atropine-bromocresol green complex solution in chloroform. This solution was subjected to UV-Vis spectroscopy to construct the atropine calibration curve. The TA content in TCC was determined as follows: 3 mL TCC solution (6 mg mL−1) was completely evaporated to remove the ethanol, the remaining extract was dissolved in 2 M HCl, and the precipitate was ltered off. The solution was neutralized with NaOH and transferred to a separatory funnel. 5 mL of bromocresol green, 5 mL of phosphate buffer, and 5 mL of chloroform were added, shaken vigorously for 2 min, and the yellow complex solution dissolved in chloroform was collected. This solution was subjected to UV-Vis spectroscopy to determine TA using the calibration curve. The TA content or concentration is expressed as atropine equivalent (AtrE). 2.2.4. Synthesis of ZnO nanoparticles using aqueous extract. Nine types of ZnO nanoparticles were synthesized by the reaction between the aqueous extract of the wormwood and zinc acetate. 10 mL, 20 mL, or 30 mL of 5 mg mL−1 TCN solution were reacted with 10 mL of 0.1 M Zn(CH3COO)2 solution at room temperature for 24 h. Aer the reaction, the precipitate was separated by centrifugation, washed with distilled water, and dried at 60 °C for 24 h before heating at 600, 500, or 400 °C. The ZnO samples are designated according to the synthesis conditions as shown in Table 1. 2.2.5. Synthesis of ZnO-extract nanoformulations. To synthesize ZnO-extract nanoformulations, the ethanol extract TCC of the Stixis scandens leaves was carried onto the ZnO nanoparticles by adsorption method.5 In a common procedure, 100 mg of ZnO nanoparticles (3 samples selected as A1, B3, and C3) were dispersed in water by ultrasonic vibration. 10 mL of the 1 mg mL−1 TCC solution was then slowly added. The mixture was maintained for 24 h with continuous magnetic stirring. ZnO nanosystems loading Stixis scandens extracts, denoted A1T, B3T, and C3T respectively, were collected by centrifugation, washed with distilled water, and dried at 60 °C for 24 h before further characterization. 2.2.6. Characterization of the synthesized nanoformulations. The size and morphology of the samples were analyzed by eld emission scanning electron microscopy (FESEM) and dynamic light scattering (DLS) methods. X-ray diffraction (XRD) was used to determine the crystal structure of the nanoformulations. The presence and composition of organic compounds in the nanoformulations were evaluated by UV-Vis absorption spectroscopy, Fourier transform infrared spectroscopy (FTIR), Raman spectroscopy, and thermal analysis method (TGA).

Open Access Article. Published on 14 March 2024. Downloaded on 5/31/2026 2:41:26 AM. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

RSC Advances The extract content in the nanoformulation (% loading content – % LC) and the encapsulation efficiency of the nanoformulation (% encapsulation efficiency – % EE) were determined based on the TP and TA content in the sample. A weighted sample (about 10 mg) of the lyophilized ZnO-extract nanoformulation was immersed in 5 mL of food-grade ethanol for 30 min to release all the extract from the nanoformulation. The solution was centrifuged at 4500 rpm for 10 min. The supernatant was aspirated with a pipette and analyzed for TP and TA according to the method in Section 2.2.3. % EL and % EE are calculated according to eqn (1) and (2), respectively. % LC = (mass of extract contained in the nanoformulation)/ (the nanoformulation) × 100% (1) % EE = (mass of extract contained in the nanoformulation)/ (mass of the initial extract) × 100% (2) The release of the active substance from the nanoparticles was determined in isotonic phosphate buffer (PBS) pH 7.4. The nanoformulation solution (5 mL) was transferred to a dialysis bag (MWCO 6–8 kDa). The sealed dialysate bag is dipped in 20 mL of PBS buffer pH 7.4. The release experiment was performed at 38.5 °C (normal body temperature of pigs) and shaken at 100 rpm. At the specied times, 2 mL of release medium was withdrawn and immediately replaced with 2 mL of fresh PBS. The collected samples were analyzed for TP and TA content. 2.2.7. In vitro PED virus treatment. The in vitro PEDV treatment experiments were carried out according to previous work with minor modications.10 Initially, the nanoformulations and dried Stixis scandens ethanolic extract (TCC) were examined for their toxicity on Vero cells (African green monkey kidney cells). TCC was diluted in DMSO to form a 1000 mg mL−1 solution while the 3 nanoformulations of A1T, B3T, and C3T were dispersed in water to form 500 mg mL−1. Serial two-fold dilutions of the samples were prepared in DMEM and then added to the Vero cell previously cultured in a 96-well plate (100 ml per well). Each sample dilution was tested in three wells and the experiments were performed in duplicate. The plate was then incubated at 37 ° C in 5% CO2. The Vero cells in the plate were observed for their morphology by an inverted microscope and daily tested for cytotoxic effects in 5 days. The maximum nontoxic concentration (MNTC) of each sample was determined as the maximum concentration of the sample at which the cells grew normally. In the next steps, the MNTC of samples was used as the starting concentration for the PEDV treatment test. Serial twofold dilutions of the samples were prepared in DMEM and then mixed with an equal volume of PED virus solution (400 TCID50/100 ml). The virus-sample mixture was incubated at 37 ° C for 30 min and then added to Vero cells previously cultured in a 96-well plate (200 ml per well) (or 100 ml virus solution per well). Each sample dilution was tested in three wells and the experiments were performed in duplicate. The plate was then incubated at 37 °C in 5% CO2 for 5 days. Untreated Vero cells infected and uninfected with PEDV, respectively, were used as controls. The cytopathic effect was monitored daily. The

Paper antiviral activity of the samples was evaluated based on the inhibition of the cytopathic effect of the virus. The minimum inhibitory concentration (MIC) was determined as the minimum concentration of the sample at which the cells grew normally in the presence of the virus. 2.2.8. Data analysis. The quantications were carried out in 3 replicates, the results were expressed as an average ± standard deviation. The data were processed using Excel 2019 and Origin 8.0 soware.

3. Results and discussion

3.1. The qualitative and quantitative composition of the extract Fig. 1 shows the fresh and dried parts of the plant Stixis scandens L. From 100 g of powdered leaves of S. scandens, 12.0 g of TCC dry extract or 15.3 g of TCN dry extract was obtained. The results of the qualitative component analysis of TCC and TCN are presented in Fig. 2. As shown in Fig. 2, the ethanol extract (TCC) of S. scandens contained alkaloids, polyphenols, avonoids, and glycosides while saponin, polyphenols, and avonoids were found in the aqueous extract (TCN). Iridoids were not found in either extract. Total polyphenols (TP) was determined in TCC and TCN and total alkaloids (TA) was estimated in TCC by UV-Vis methods. The calibration curves for the polyphenol standard (gallic acid) and the alkaloid standard (atropine) are shown in Fig. 3. The TP content was determined to be 56.94 ± 0.46 mg GAE per mg dried TCN and 38.51 ± 0.25 mg GAE per mg dried TCC. The TA content was 22.37 ± 0.41 mg AtrE per mg in dried TCC. 3.2. ZnO nanoparticles FESEM images, UV-Vis spectra, and XRD patterns of ZnO nanoparticles are shown in Fig. 4. As summarized in Table 2, Fig. 1

Stixis scandens L. plant collected at Vu Quang, Ha Tinh, Vietnam. © 2024 The Author(s). Published by the Royal Society of Chemistry View Article Online

Open Access Article. Published on 14 March 2024. Downloaded on 5/31/2026 2:41:26 AM. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Paper RSC Advances

Fig. 2 Qualitative analysis of chemical compositions of aqueous and ethanolic extracts. the differences in synthesis conditions lead to different sizes of the obtained ZnO nanoparticles determined by the FESEM method. In general, the higher calcination temperature resulted in larger particles. This result is consistent with other previous observations.35 All the samples absorb at the maximum wavelength from 375 to 384 nm conrming the formation of hexagonal wurtzite ZnO NPs in the samples. The absorptions are assigned to the transition of the electrons in the ZnO structures.36 The band gap energy of the ZnO NPs was determined by taking the linear part of (ahn)2 versus hn plot. While the amount of TCN solution used in the ZnO synthesis process shows no clear effect on the change in the size and shape of the ZnO-NPs (in the FESEM images), increasing the amount of TCN seems to decrease the band gap of the samples at the same temperature (A, B or C series). In a recent report, the author used Citrus microcarpa extract at different concentrations of 1%, 2%, and 4% (w/v) to synthesize ZnO NPs. The results showed that the band gap values of the synthesized ZnO NPs decreased with increasing extract concentration.37 In the XRD patterns of all samples, the typical peaks appear at 2q of 31.75°, 34.41°, 36.23°, 47.53°, 56.58°, 62.84°, 66.61°, 68.32° and 69.12° corresponding to the (100), (002), (011), (102), (110), (103), (200), (112) and (201) of the hexagonal wurtzite crystal structure of ZnO NPs.36,38 Furthermore, no strange peaks are present in the patterns. This conrms that the ZnO NPs were successfully synthesized in crystalline form. The average particle size of the ZnO crystals was calculated by the Scherrer method using eqn (3) and the Williamson–Hall (W–H) plot method using eqn (4) (ref. 39) and presented in Table 2. D¼ bhkl cos qhkl ¼

where D is the crystallite size of the particle, K is the Scherrer constant (K = 0.9), l is the wavelength of the incident X-rays (l = 0.1540 nm), b is the full width at half maximum of the © 2024 The Author(s). Published by the Royal Society of Chemistry

UV-Vis spectra and calibration curves of TP as gallic acid (a) and TA as atropine (b). Fig. 3 diffraction peak and q is the reection angle, 3 is the straininduced broadening due to crystal imperfection and distortion.

RSC Adv., 2024, 14, 8779–8789 | 8783

The XRD data are rather well-tted to the linear model between b cos q and 4 sin q in the W–H equation (R2 > 0.90). The crystallite sizes of the samples calculated by the W–H method 8784 | RSC Adv., 2024, 14, 8779–8789

D (nm) 60–90 60–120 30–120 30–90 30–90 40–60 20–60 20–40 30–50 Sample A1 A2 A3 B1 B2 B3 C1 C2 C3 FESEM 381 383 376 375 378 384 380 376 375 lmax (nm) UV-Vis 2.15 2.0 1.8 2.65 2.2 2.3 2.35 2.15 2.1 Band gap (eV)

Size (diameter – D), absorption band and band gap of ZnO nanoparticles

Fig. 4 FESEM images (a), UV-Vis spectra (b), Tauc's plots (c), XRD patterns (d), and Williamson–Hall plots (e) of ZnO nanoparticles. Table 2 0.0014 0.0025 0.0022 0.0015 0.0025 0.0019 0.0015 0.0029 0.0026

3 D (nm) 34.0 28.6 32.6 33.9 26.3 28.7 30.5 24.0 22.9 W–H method Scherrer method XRD 0.00414 0.00473 0.00459 0.00444 0.00425 0.00490 0.00446 0.00531 0.00592 Kl D 0.9718 0.9807 0.9790 0.9079 0.9875 0.9788 0.9402 0.9849 0.9919

R2

Open Access Article. Published on 14 March 2024. Downloaded on 5/31/2026 2:41:26 AM. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. 33.5 29.3 30.2 31.2 32.6 28.3 31.2 26.1 23.4

D (nm) View Article Online RSC Advances Paper © 2024 The Author(s). Published by the Royal Society of Chemistry View Article Online

Open Access Article. Published on 14 March 2024. Downloaded on 5/31/2026 2:41:26 AM. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Paper RSC Advances

are in good agreement with those calculated by the Scherrer method. The slight difference in the average crystallite size calculated with the two equations is due to the different averaging of the particle size distribution.39 The Raman spectra of the samples were also recorded (Fig. 5a). In the Raman spectra, the E2 phonon mode appears sharply at about 435 cm−1. This mode is typical for the hexagonal wurtzite structure of ZnO NPs. The higher intensity of the E2 mode of the A and B series compared to that of the C series is related to the larger particle size of these samples.40,41 Another strong peak appears at about 520 cm−1, which is assigned to the A1 (LA) mode while the peak at 660 cm−1 is assigned to the two phonon vibrational modes of A (LO) and E (low).42

Raman (a) and photoluminescence spectra (b) of ZnO nanoparticles. Fig. 5 Table 3

3.3. ZnO-extract nanoformulation The TCC extract was incorporated into A1, B3, C3 to form 3 nanoformulations of A1T, B3T, and C3T, respectively. The TA and TP contents in the nanoformulations were determined. Based on the TA and TP contents, the LC and EE values of the ethanolic extract in the nanoformulations were also calculated and the results are shown in Table 3. It can be seen that the TP is less loaded to the ZnO NPs than the TA (lower LC and EE). This could be due to the higher solubility of the polyphenols in aqueous environment than that of the alkaloids. The difference in the loading contents of TA and TP may lead to different biological effects. Recently, Kim et al. reported that ZnO NPs in combination with one of two polyphenols (rutin and quercetin) can cause higher cytotoxicity, but in different levels.43 Polyphenols are powerful antioxidants and can inhibit the growth of viruses both in vitro and in vivo, acting on different stages of viral infection. In addition, polyphenols are non-toxic to human and animal cells.44–46 Many alkaloids also exhibit highly specic antiviral activity.47 For example, lycorine, an alkaloid isolated from Narcissus pseudonarcissus, has been shown to have antiviral properties in vitro and can protect AG6 mice from Zika virus-induced death by reducing the viral load in the mice's blood.48 Homoharringtonine, another alkaloid, was found to be resistant to PEDV and reduced viral load and severe symptoms at a dose of 0.5 mg kg−1.49 Therefore, the TA and TP content could confer an antiviral effect on the nanoformulations. Fig. 6 shows the properties of the ZnO-extract nanoformulations. In the FESEM images, the surface of the nanoformulations becomes blurrier than that of the ZnO NPs (Fig. 6a), which is due to the coverage by organic compounds in the TCC. We also observed a similar phenomenon in the ZnO nanoformulation with Paederia lanuginosa leaf extract.50 Fig. 6b shows some slight blue shis appearing in the UV-Vis spectra of A1T, B3T, and C3T compared to TCC at around 665, 620, 545, and 455 nm. This indicates that there is an interaction between the ZnO NPs and the compounds in TCC. In Fig. 6c, the O–H stretching appears at 3450 cm−1 while the –C–H stretching can be observed at 2919 cm−1 and 2852 cm−1. The peak at 1429 cm−1 is due to the C–H bending. The peaks at 837 and 872 cm−1 belong to the C]C bending. These peaks in the FTIR spectra conrm the presence of the functional groups of the organic compounds in the nanoformulations. Moreover, the peak at 567 cm−1 is due to the presence of the Zn–O bond. These evidences reveal that the nanoformulations were successfully prepared.25 Fig. 6d and Table 4 show the results of the TGA analysis. The ZnO nanoformulations underwent weight loss in 2 or 3 steps

LC (%) LC (%) EE (%) EE (%) % TP release % TP release % TA release % TA release Sample (calculated from TP) (calculated from TA) (calculated from TP) (calculated from TA) (pH 7.4 72 h) (pH 5 72 h) (pH 7.4 72 h) (pH 5 72 h) A1T B3T C3T

5.1  0.3 4.5  0.3 4.7  0.2 6.3  0.4 5.4  0.2 5.7  0.3 53.7  3.0 47.1  3.0 49.3  2.0 © 2024 The Author(s). Published by the Royal Society of Chemistry 67.2  4.0 57.1  2.0 60.4  3.0 85.9  0.6 80.7  0.4 78.3  0.4

96.0  0.8 91.2  0.6 92.1  0.7 46.2  0.7 42.9  0.7 44.3  0.7 76.3  0.5 70.2  0.3 67.4  0.2 RSC Adv., 2024, 14, 8779–8789 | 8785 View Article Online Paper

Open Access Article. Published on 14 March 2024. Downloaded on 5/31/2026 2:41:26 AM. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. RSC Advances Fig. 6

FESEM images (a), UV-Vis spectra (b), FTIR spectra (c), and TGA and dTG diagram (d) of ZnO-extract nanoformulations. Table 4 Weight loss steps of ZnO-extract nanoformulations Step 1 Step 2 Step 3 Sample

Temp. range (°C) % weight loss (a) Temp. range (°C) % weight loss (b) Temp. range (°C) % weight loss (c) % organic mattera A1T B3T C3T 20–200 2 0.49 1.24 200–500 200–500 200–900 6.69 2.96 6.57 500–900 500–900 —

0.79 2.81 — 7.6% 5.8% 6.7% a % organic matter ¼ ðbÞ þ ðcÞ  100%: 100  ðaÞ 8786 | RSC Adv., 2024, 14, 8779–8789 © 2024 The Author(s). Published by the Royal Society of Chemistry View Article Online

Open Access Article. Published on 14 March 2024. Downloaded on 5/31/2026 2:41:26 AM. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Paper RSC Advances

during the heating process from room temperature to 900 °C. The rst step takes place at around 100 °C, which corresponds to weight loss through water evaporation. The second step of the three nanoformulations takes place at 200 to 500 °C and the third step for A1T and B3T at 500 to 900 °C, while no weight loss was observed for C3T from 500 to 900 °C. These steps are the result of the decomposition of the organic matter in the samples.23 In addition, the dTG peaks in the 200–500 °C region of the 3 samples are in different positions in the 3 samples. The differences in the thermal activity of the samples indicate that the nanoformulations were loaded with different compositions of Stixis scandens extract. From the TGA results, it can be calculated that the content of organic compounds in A1T, B3T and C3T is 7.6%, 5.8%, and 6.7%, respectively. This result agrees well with the content calculated using the UV-Vis method (Table 3). Fig. 7 shows the release prole of A1T in the form of TP and TA at pH 5 and pH 7.4. The percentage release aer 72 h for the 3 nanoformulations is shown in Table 3. TP is released faster than TA at both pH values, and the acidic environment (pH 5) favors the release of both TA and TP from the nanoformulations. Similar observations were made when comparing the release of allicin and phyllanthin from their Ag nanoparticles.51 TA is more loaded and less released in the nanoformulations than TP (Table 3), suggesting that TA may contribute more to the biological activities of the nanoformulations than TP. As pointed out in a review article, some alkaloids have EC50 inhibitory concentrations against PEDV of 13.41 ± 1.13 mM, 4.49 ± 0.67 mM, and 6.17 ± 0.50 mM, respectively. Homoharringtonine, another alkaloid—even completely suppressed PEDV infection at a concentration of 500 nM.52 Polyphenols such as EGCG require higher concentrations to inhibit PEDV (EC50 = 83.18 mM).53

Fig. 8 Cytotoxicity results (a), uninfected Vero cells (mocks) (b), Vero TCC A1T B3T C3T 31.2 3.9 15.6 3.9 15.6 — 7.8 — © 2024 The Author(s). Published by the Royal Society of Chemistry

cells infected with non-treated PEDV (c), Vero cells infected with 3.9 mg mL−1-A1T-treated PEDV (d), Vero cells infected with 7.8 mg mL−1C3T-treated PEDV (e). RSC Adv., 2024, 14, 8779–8789 | 8787 View Article Online

Open Access Article. Published on 14 March 2024. Downloaded on 5/31/2026 2:41:26 AM. This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

RSC Advances Table 5 and Fig. 8 show the results of the cytotoxicity and PEDV treatment experiments. The C3T has higher cytotoxicity on Vero cells (lower MNTC) than B3T and A1T. This could be related to the smaller size of the ZnO NPs in the C3T nanoformulation.54,55 While B3T and C3T show no PEDV inhibitory activity at MNTC, the A1T nanoformulation and the extract alone (TCC) have the same value of MIC of 3.9 (mg mL−1). The extract content in B3T and C3T may not be high enough to inhibit PEDV. However, in the A1T, the extract accounted for only 7.6% of the nanoformulation and has equivalent antiviral activity to 100% extract. This conrms that the nanoformulation improved the antiviral activity of the plant extract. In another study, it was reported that the chitosan–silica nanoformulation of Echinacea purpurea ethanol extract showed better biological effects than the extract alone.47

4. Conclusions In summary, the preparation and characterization of ZnO NPs with an aqueous extract from the leaves of Stixis scandens was successful. Changing the calcination temperature and the volume ratio between the extract and the Zn precursor resulted in different sizes of ZnO-NP obtained. TCC, the ethanolic extract of Stixis scandens with a TP content of 38.51 ± 0.25 mg GAE per mg and TA content of 22.37 ± 0.41 mg AtrE per mg, was incorporated into the ZnO-NPs to form three nanoformulations of A1T, B3T, and C3T. These nanoformulations contained 5.8–7.6% extract, with TP being less loaded but more released than TP. A1T with the highest extract content showed equivalent PEDV inhibitory activity as the extract alone. Although these results are promising for the development of nanoformulations for the treatment of PEDV, further studies should be conducted to clarify how the nanoformulations inhibit the development of PEDV and which compounds in the extract play a crucial role in the inhibition.

Author contributions L. T. T. H.: conceptualization, funding acquisition, investigation, writing original dra. T. T. T. and L. T. N. H.: investigation, L. V. P.: supervision, methodology, review and editing.

Conflicts of interest There are no conicts to declare.

📖 中文全文 Chinese Full Text

中文

# 中文翻译

开放获取文章。发表于2024年3月14日。下载于2026年5月31日凌晨2:41:26。 本文采用知识共享署名-非商业性使用3.0未本地化版本许可协议授权。RSC Advances 在线查看文章

论文 引用本文:RSC Adv., 2024, 14, 8779 查看期刊 | 查看期号

**用于猪流行性腹泻病毒(PEDV)治疗的Stixis scandens叶提取物负载ZnO纳米颗粒**

Thi Thu Huong Le, a Thi Tam Than, b Thi Ngọc Ha Lai c 和 Van Phan Le *c

猪流行性腹泻(PED)是给畜牧业者造成巨大损失的疾病之一。由于针对该疾病的疫苗效果不佳,市场迫切需要具有有效抗PED病毒(PEDV)能力的生物制品。当今最重要的趋势之一是在畜牧业中使用天然来源的活性成分。本研究旨在从已被证明能抑制PEDV的Stixis scandens提取物中开发出一种有效的抗PEDV制剂。首先制备了Stixis scandens叶的水提物(标记为TCN)和醇提物(标记为TCC),并对其化学成分进行了定性分析。利用TCN合成了粒径从20至120 nm不等的ZnO纳米颗粒(NPs)。随后,将TCC负载到ZnO NPs上,形成提取物负载含量为5.8–7.6%的ZnO-提取物纳米制剂。TCC中总多酚(TP)和总生物碱(TA)含量分别为38.51 ± 0.25 mg GAE/mg和22.37 ± 0.41 mg AtrE/mg。TP在纳米制剂中的负载量较低但释放量高于TA。仅含7.6%提取物的A1T纳米制剂对PEDV的最小抑制浓度为3.9 mg mL−1,与TCC相当。实验证实,该纳米制剂在PEDV抑制应用中具有良好的前景。

## 1. 引言

猪流行性腹泻(PED)是由病毒引起的猪业中最重要的疾病之一。PEDV是一种正义单链RNA病毒,属于冠状病毒科(Coronavirinae)。1 该科病毒在哺乳动物和鸟类中引起多种疾病,从牛和猪的肠炎到鸡的上呼吸道疾病,以及人类的致命性呼吸道感染,如严重急性呼吸综合征(SARS)、中东呼吸综合征(MERS)和新冠肺炎(COVID-19,SARS-CoV-2)。2 PEDV可引起各日龄猪的严重水样腹泻及随后的脱水,并在7–10日龄仔猪中造成高死亡率。尽管已有多种疫苗被用于预防PEDV,包括减毒活疫苗、重组载体疫苗、DNA疫苗和亚单位疫苗,但由于这些疫苗通常效果不佳,仍无法有效预防PED的暴发。3 因此,迫切需要抗病毒生物制品用于疾病预防和治疗。此前的一些研究已发现了多种具有抗PEDV活性的化合物,如2-脱氧-D-葡萄糖、4 甘草酸、5 和表面活性素。6 然而,目前尚无有效的商业化药物可控制PEDV感染。

天然产物长期以来被广泛研究作为抗病毒剂。7 近年来,针对具有天然抗PEDV活性物质的研究受到广泛关注。例如,从番茄皮和叶中提取的甾体生物碱番茄碱(tomatidine)在体外对Vero和IPEC-J2细胞中的PEDV复制表现出显著抑制作用。研究发现,番茄碱抑制PEDV的机制主要是通过3CL蛋白酶发挥作用。此外,番茄碱在体外对传染性胃肠炎病毒(TGEV)、猪繁殖与呼吸综合征病毒(PRRSV)、脑心肌炎病毒(EMCV)和塞内卡病毒A(SVA)也具有抗病毒活性。2 在另一项研究中,辣木(M. oleifera)叶的水提物能够在体外抑制PEDV感染复制阶段的进程。此外,M. oleifera提取物通过阻止PEDV感染引起的氧化应激和细胞凋亡来抑制PEDV感染。8 芦荟提取物在浓度为16 mg mL−1时可抑制PEDV在体外的复制,并在病毒生命周期的晚期阶段发挥抑制作用。浓度为100 mg/kg体重的芦荟提取物在小鼠中具有相对安全性,可降低猪肠道中的病毒载量和病理变化,并保护仔猪免受PEDV GDS01株的实验性毒性侵害。9 在先前的一项研究中,对多种越南药用植物进行了筛选,确定Stixis scandens叶的醇提物相比其他提取物是最有效的抗PEDV制剂。10

Stixis scandens,又称Stixis elongata Pierre,属于山柑科(Capparidaceae),民间用于治疗筋骨疼痛和风湿病,其叶用于治疗眼疾。11 据我们所知,对该植物的化学成分研究较为有限。2023年的一项研究报道在Stixis scandens叶的组成中发现了两种新的含N糖苷化合物。12 同科植物Stixis suaveolens Roxb的部分化学成分已有研究报道。13 越南科学家已从Stixis suaveolens Roxb植物中开发了提取化合物Cappariloside A的方法。14 该化合物属于生物碱类,已被证明具有抗多种病毒的能力,包括流感病毒H1N1和H3N2、副流感病毒3型(PIV3)和腺病毒(ADV)。15

尽管植物提取物能抑制病毒生长,但其效果取决于活性化合物的浓度。由于这些化合物还具有抗营养特性,植物提取物在动物饲料中的添加量受到限制,否则可能影响或降低饲料采食量或营养物质消化率。16 此外,在上述体内试验中,尽管芦荟提取物显示出对PEDV的抗性,但高浓度的提取物可能增加仔猪的血液黏度并引起轻度腹泻。9 因此,提高植物提取物的疗效并降低其剂量对于PEDV治疗应用至关重要。

开发植物源药物的纳米制剂是治疗多种病毒性疾病的一个有前景的趋势。17 目前已有多种纳米制剂被用作抗病毒药物递送载体,如脂质纳米系统、聚合物纳米系统、脂质-聚合物纳米系统、碳纳米复合材料、金属纳米/无机金属氧化物等。18 其中,纳米ZnO纳米制剂展现出巨大潜力。氧化锌(ZnO)长期以来被用作减少仔猪腹泻的制剂。在一项关于ZnO对PEDV感染仔猪影响的研究中,结果表明以100 mg/kg体重的剂量使用ZnO可改善PEDV感染仔猪的生长性能、肠道氧化还原状态和肠道形态与功能,并减轻腹泻。ZnO可通过调节中性粒细胞脱颗粒对PEDV感染仔猪发挥抗病毒和抗炎作用。然而,该研究使用的是非纳米级ZnO颗粒。19 从营养学角度看,纳米级锌补充剂在动物体内的生物利用度高于微米级锌,可在肠道中发生更多相互作用并被更好地吸收。20 在猪日粮中使用纳米锌可将所需锌的量减少高达60%,且不影响对肠道微生物群的作用。21 ZnO纳米颗粒能够抑制多种病毒,如H1N1、22,23 HSV-1(ZnO-PEG纳米颗粒在200 mg mL−1浓度下使病毒滴度降低2.5 log10 TCID50,并使该病毒的DNA拷贝数减少92%)24 或使用白花丹(Plumbago indica L.)植物提取物合成的ZnO纳米颗粒,其CC50(50%细胞毒性浓度)和IC50分别为43.96 ± 1.39和23.17 ± 2.29 mg mL−1。25 2023年,手性ZnO纳米颗粒的抗病毒活性也被研究。26 在该研究中,L-ZnO纳米颗粒对猪繁殖与呼吸综合征病毒(PRRSV)的抗病毒活性高于D-ZnO和DL-ZnO。近年来,许多研究报道了纳米ZnO在抑制SARS-CoV-2方面的潜力。例如,PEG化ZnO纳米颗粒的IC50 = 526 ng mL−1;CC50/IC50 > 1.27。27 用不同酚类化合物合成的ZnO纳米颗粒在计算机模拟模型中被预测能够抑制SARS-CoV-2。28 在2022年发表的一篇综述中,作者阐述了ZnO纳米颗粒的抗病毒机制,并证实锌(一种必需微量元素)的补充,尤其是纳米形式的锌,有助于支持新冠肺炎的预防和治疗。29 ZnO纳米颗粒(30–60 nm)对SARS-CoV-2 Delta和Omicron变异株的灭活效果优于较大粒径的ZnO纳米颗粒。30 对于PEDV,我们仅发现一份摘要报告表明ZnO可灭活PEDV,但不破坏该病毒颗粒。31 在本研究中,从Stixis scandens叶中制备了醇提物和水提物,并测定了其化学成分。此外,这是首次将Stixis scandens叶的水提物和醇提物均用于合成ZnO纳米制剂以治疗PEDV。

## 2. 实验部分

### 2.1. 材料

Stixis scandens叶采集于越南河静省武光(Vu Quang),植物学名经越南国家自然博物馆鉴定。叶片经清洗后于40 °C干燥24 h,然后研磨成细粉并储存于密封容器中。

所用试剂包括:食用酒精(96°)、蒸馏水、硫酸阿托品标准品、溴甲酚绿、没食子酸标准品、Folin-Ciocalteu试剂、Zn(CH3COO)2·2H2O,其他常用试剂均为分析级,未经纯化直接使用。

### 2.2. 研究方法

#### 2.2.1. Stixis scandens叶提取物的制备 将100 g Stixis scandens叶粉末浸泡于2 L蒸馏水或2 L 96°乙醇中48 h,每24 h结合超声振荡3次,每次间隔30 min,每次15 min,室温下进行。提取液依次经棉塞和Whatman®滤纸(1号)过滤后用于定性测定。为测定提取物的总多酚、总生物碱及抗病毒活性,使用旋转蒸发仪在低温(40 °C)和减压条件下浓缩提取物,然后冷冻干燥至恒重,储存于4 °C密封容器中。叶的水提物和醇提物分别标记为TCN和TCC。

#### 2.2.2. Stixis scandens化学成分的定性测定 提取物的植物化学成分测定采用通用方法并稍作修改。32,33

**酚类化合物**:采用FeCl3试验测定。取1.0 mL TCN或TCC与1.0 mL 0.1 M FeCl3溶液混合,溶液颜色变化表明多酚化合物的存在。

**皂苷**:采用泡沫试验和Fehling试验。将0.5 mL TCC或TCN用2.0 mL蒸馏水稀释,在试管中剧烈搅拌,形成的稳定泡沫表明皂苷的存在。Fehling试剂的配制:将1.0 mL 1 M CuSO4、1.0 mL 2 M NaOH和1.0 mL 10%酒石酸钾钠溶液混合。将Fehling试剂加入1.0 mL TCC或TCN中,加热后出现红色沉淀进一步证实皂苷的存在。

**生物碱**:使用Dragendorff试剂检测。Dragendorff试剂由过量5% KI溶液与Bi(NO3)3溶液在酸性介质中反应合成。将TCN和TCC点样于硅胶板上,浸入Dragendorff试剂溶液中,提取位点出现橙色表明生物碱的存在。

**糖苷**:取1.0 mL乙酸和1.0 mL氯仿与1.0 mL TCN或TCC混合,将混合物置于冰浴烧杯中,加入浓H2SO4,溶液呈现绿色表明提取物中含有糖苷。

**环烯醚萜**:使用Trim-Hill试剂(乙酸 - 0.2% CuSO4 - 浓HCl,10:1:0.5)测定。将0.5 mL TCC或TCN加入4 mL Trim-Hill试剂中混匀,蓝色出现表明环烯醚萜的存在。

**黄酮类化合物**:TCC或TCN与1 mL 5% NaNO2、1 mL 10% Al(NO3)3和10 mL 4% NaOH溶液的混合物反应,黄色确认黄酮类化合物的存在。

#### 2.2.3. 提取物中总多酚(TP)和总生物碱(TA)的定量分析 提取物中TP和TA的分析参照已发表的方法进行。34

**2.2.3.1. 基于没食子酸标准物质的TP测定** 将没食子酸用水稀释至200 mg mL−1的储备液,配制浓度为20、40、60、80和100 mg mL−1的标准系列。Folin-Ciocalteu试剂稀释10倍。取0.5 mL没食子酸标准溶液,加入2.5 mL稀释的Folin-Ciocalteu试剂和2 mL 7.5% Na2CO3溶液,静置2 h后记录标准系列的紫外-可见光谱,确定最大吸收波长并建立没食子酸标准曲线。

TCC和TCN中TP含量的测定方法与标准系列测量类似,将0.5 mL标准溶液替换为0.5 mL TCC或TCN溶液(TCC:1.2 mg mL−1乙醇溶液,TCN:1 mg mL−1水溶液)。提取物中的TP含量根据标准曲线计算,以没食子酸当量(GAE)表示。

**2.2.3.2. 基于阿托品标准物质的TA测定** 精密称取10.8 mg硫酸阿托品((C17H24NO3)2·SO4·H2O,M = 694.8 g mol−1),溶于50 mL蒸馏水中,得到180 mg mL−1的阿托品标准储备液(C17H23NO3,M = 289 g mol−1)。从阿托品标准溶液配制浓度为5、9、18、27、36 mg mL−1的阿托品标准系列。

在碱性环境(NaOH)中配制浓度为1 mmol L−1的溴甲酚绿溶液,配制0.1 M NaH2PO4缓冲液(pH = 4.7)。取3 mL阿托品标准溶液,加入5 mL溴甲酚绿溶液、5 mL磷酸盐缓冲液和5 mL氯仿于分液漏斗中,剧烈振荡2 min,取氯仿中可溶性黄色阿托品-溴甲酚绿络合物溶液,进行紫外-可见光谱分析以构建阿托品标准曲线。

TCC中TA含量的测定方法如下:将3 mL TCC溶液(6 mg mL−1)完全蒸发除去乙醇,残余提取物溶于2 M HCl中,过滤除去沉淀。溶液用NaOH中和后转移至分液漏斗中,加入5 mL溴甲酚绿、5 mL磷酸盐缓冲液和5 mL氯仿,剧烈振荡2 min,收集溶于氯仿的黄色络合物溶液,进行紫外-可见光谱分析,利用标准曲线测定TA。TA含量或浓度以阿托品当量(AtrE)表示。

#### 2.2.4. 使用水提物合成ZnO纳米颗粒 通过Stixis scandens水提物与醋酸锌的反应合成了九种类型的ZnO纳米颗粒。将10 mL、20 mL或30 mL的5 mg mL−1 TCN溶液与10 mL 0.1 M Zn(CH3COO)2溶液在室温下反应24 h。反应后,沉淀经离心分离,用蒸馏水洗涤,60 °C干燥24 h后,再分别于600、500或400 °C煅烧。ZnO样品根据合成条件标记,如表1所示。

#### 2.2.5. ZnO-提取物纳米制剂的合成 为合成ZnO-提取物纳米制剂,通过吸附法将Stixis scandens叶的醇提物TCC负载到ZnO纳米颗粒上。5 在常规操作中,将100 mg ZnO纳米颗粒(选择A1、B3和C3三个样品)通过超声振荡分散于水中,然后缓慢加入10 mL 1 mg mL−1 TCC溶液。混合物在持续磁力搅拌下保持24 h。负载Stixis scandens提取物的ZnO纳米系统分别标记为A1T、B3T和C3T,经离心收集,用蒸馏水洗涤,60 °C干燥24 h后进行进一步表征。

#### 2.2.6. 合成纳米制剂的表征 样品的尺寸和形貌通过场发射扫描电子显微镜(FESEM)和动态光散射(DLS)方法分析。X射线衍射(XRD)用于测定纳米制剂的晶体结构。通过紫外-可见吸收光谱、傅里叶变换红外光谱(FTIR)、拉曼光谱和热分析方法(TGA)评估纳米制剂中有机化合物的存在和组成。

纳米制剂中的提取物含量(%负载含量 - %LC)和纳米制剂的包封效率(%包封效率 - %EE)根据样品中TP和TA的含量测定。精密称取约10 mg冻干的ZnO-提取物纳米制剂,浸入5 mL食用级乙醇中30 min,使所有提取物从纳米制剂中释放。溶液在4500 rpm下离心10 min,用移液管吸取上清液,按第2.2.3节方法分析TP和TA。%LC和%EE分别按公式(1)和(2)计算:

%LC =(纳米制剂中所含提取物质量)/(纳米制剂质量)× 100% (1)

%EE =(纳米制剂中所含提取物质量)/(初始提取物质量)× 100% (2)

活性物质从纳米颗粒中的释放测定在等渗磷酸盐缓冲液(PBS)pH 7.4中进行。将纳米制剂溶液(5 mL)转移至透析袋(截留分子量6–8 kDa)中,将密封的透析袋浸入20 mL pH 7.4的PBS缓冲液中。释放实验在38.5 °C(猪的正常体温)下以100 rpm振荡进行。在指定时间点取出2 mL释放介质,立即补充2 mL新鲜PBS。收集的样品进行TP和TA含量分析。

#### 2.2.7. 体外PED病毒处理 体外PEDV处理实验参照先前工作稍作修改进行。10 首先,检测纳米制剂和干燥的Stixis scandens醇提物(TCC)对Vero细胞(非洲绿猴肾细胞)的毒性。TCC用DMSO稀释成1000 mg mL−1溶液,三种纳米制剂A1T、B3T和C3T分散于水中形成500 mg mL−1。将样品在DMEM中进行系列二倍稀释,然后加入预先在96孔板中培养的Vero细胞中(每孔100 μL)。每个样品稀释度设三个复孔,实验重复两次。然后将平板在37 °C、5% CO2条件下培养。通过倒置显微镜每日观察平板中Vero细胞的形态,连续5天检测细胞毒性效应。每个样品的最大无毒浓度(MNTC)确定为细胞正常生长的最大样品浓度。

在后续步骤中,以样品的MNTC作为PEDV处理测试的起始浓度。将样品在DMEM中进行系列二倍稀释,然后与等体积的PED病毒溶液(400 TCID50/100 μL)混合。病毒-样品混合物在37 °C孵育30 min,然后加入预先在96孔板中培养的Vero细胞中(每孔200 μL,或每孔100 μL病毒溶液)。每个样品稀释度设三个复孔,实验重复两次。平板在37 °C、5% CO2条件下培养5天。分别以未经处理的PEDV感染和未感染的Vero细胞作为对照。每日监测细胞病变效应(CPE)。基于对病毒细胞病变效应的抑制评估样品的抗病毒活性。最小抑制浓度(MIC)确定为在病毒存在下细胞正常生长的最低样品浓度。

#### 2.2.8. 数据分析 定量分析进行3次重复,结果以平均值±标准偏差表示。数据使用Excel 2019和Origin 8.0软件处理。

## 3. 结果与讨论

### 3.1. 提取物的定性和定量组成 图1展示了Stixis scandens L.植物的新鲜和干燥部分。从100 g S. scandens叶粉末中获得12.0 g TCC干燥提取物或15.3 g TCN干燥提取物。TCC和TCN的定性成分分析结果如图2所示。

如图2所示,S. scandens的醇提物(TCC)含有生物碱、多酚、黄酮类化合物和糖苷,而水提物(TCN)中检出皂苷、多酚和黄酮类化合物。两种提取物中均未检出环烯醚萜。

通过紫外-可见方法测定了TCC和TCN中的总多酚(TP),并估算了TCC中的总生物碱(TA)。多酚标准品(没食子酸)和生物碱标准品(阿托品)的标准曲线如图3所示。

经测定,TCN干燥品中TP含量为56.94 ± 0.46 mg GAE/mg,TCC干燥品中为38.51 ± 0.25 mg GAE/mg。TCC干燥品中TA含量为22.37 ± 0.41 mg AtrE/mg。

### 3.2. ZnO纳米颗粒 ZnO纳米颗粒的FESEM图像、紫外-可见光谱和XRD图谱如图4所示。如表2总结,图1

在越南河静省武光采集的Stixis scandens L.植物。© 2024 作者。由英国皇家化学会出版 在线查看文章

开放获取文章。发表于2024年3月14日。下载于2026年5月31日凌晨2:41:26。 本文采用知识共享署名-非商业性使用3.0未本地化版本许可协议授权。 论文 RSC Advances

图2 水提物和醇提物化学成分的定性分析。合成条件的差异导致通过FESEM方法测得的所得ZnO纳米颗粒尺寸不同。一般而言,较高的煅烧温度导致较大的颗粒。该结果与其他先前的观察结果一致。35

所有样品在375至384 nm的最大波长处吸收,证实了样品中六方纤锌矿ZnO NPs的形成。这些吸收归属于ZnO结构中电子的跃迁。36 ZnO NPs的带隙能量通过取(αhν)²对hν图的线性部分确定。虽然在ZnO合成过程中使用的TCN溶液量对ZnO-NPs的尺寸和形状变化没有明显影响(在FESEM图像中),但在相同温度下(A、B或C系列),增加TCN的量似乎会降低样品的带隙。在最近的一项研究中,作者使用不同浓度(1%、2%和4%,w/v)的Citrus microcarpa提取物合成ZnO NPs,结果表明合成的ZnO NPs的带隙值随提取物浓度的增加而降低。37

在所有样品的XRD图谱中,特征峰出现在2θ为31.75°、34.41°、36.23°、47.53°、56.58°、62.84°、66.61°、68.32°和69.12°处,分别对应于ZnO NPs六方纤锌矿晶体结构的(100)、(002)、(011)、(102)、(110)、(103)、(200)、(112)和(201)晶面。36,38 此外,图谱中未出现异常峰,这证实了ZnO NPs以结晶形式成功合成。ZnO晶体的平均粒径通过Scherrer方法(公式3)和Williamson-Hall(W-H)作图法(公式4)39 计算,结果列于表2。

D = Kλ / (βhkl cosθhkl)

其中D为颗粒的晶粒尺寸,K为Scherrer常数(K = 0.9),λ为入射X射线波长(λ = 0.1540 nm),β为衍射峰的半高全宽,θ为反射角,ε为晶体缺陷和畸变引起的应变展宽。

XRD数据与W-H方程中βcosθ和4sinθ之间的线性模型拟合良好(R² > 0.90)。通过W-H方法计算的样品晶粒尺寸与通过Scherrer方法计算的晶粒尺寸基本一致。两种方程计算的平均晶粒尺寸的微小差异是由于颗粒尺寸分布的平均方式不同所致。39

样品的拉曼光谱也被记录(图5a)。在拉曼光谱中,E2声子模式在约435 cm−1处尖锐出现,该模式是ZnO NPs六方纤锌矿结构的特征。与C系列相比,A和B系列的E2模式强度更高,这与这些样品的较大颗粒尺寸有关。40,41 另一个强峰出现在约520 cm−1处,归属于A1(LA)模式,而660 cm−1处的峰归属于A(LO)和E(low)的双声子振动模式。42

图5 ZnO纳米颗粒的拉曼光谱(a)和光致发光光谱(b)。 表3

### 3.3. ZnO-提取物纳米制剂 将TCC提取物掺入A1、B3、C3中,分别形成A1T、B3T和C3T三种纳米制剂。测定了纳米制剂中TA和TP的含量。根据TA和TP含量,还计算了纳米制剂中醇提物的LC和EE值,结果如表3所示。可以看出,TP在ZnO NPs上的负载量低于TA(LC和EE较低),这可能是由于多酚在水环境中的溶解度高于生物碱。TA和TP负载含量的差异可能导致不同的生物效应。最近,Kim等人报道ZnO NPs与两种多酚(芦丁和槲皮素)之一组合可导致更高水平的细胞毒性,但程度不同。43 多酚是强效抗氧化剂,可在体外和体内抑制病毒感染,作用于病毒感染的不同阶段。此外,多酚对人类和动物细胞无毒。44–46 许多生物碱也表现出高度特异性的抗病毒活性。47 例如,从石蒜(Narcissus pseudonarcissus)中分离的生物碱石蒜碱(lycorine)已被证明具有体外抗病毒特性,并能通过降低小鼠血液中的病毒载量保护AG6小鼠免受寨卡病毒引起的死亡。48 另一种生物碱高三尖杉酯碱(homoharringtonine)对PEDV具有抗性,在0.5 mg kg−1剂量下可降低病毒载量和严重症状。49 因此,TA和TP含量可赋予纳米制剂抗病毒效应。

图6展示了ZnO-提取物纳米制剂的性质。在FESEM图像中,纳米制剂的表面比ZnO NPs更模糊(图6a),这是由于TCC中有机化合物的覆盖所致。我们在含有毛胡蔓藤(Paederia lanuginosa)叶提取物的ZnO纳米制剂中也观察到了类似现象。50 图6b显示,与TCC相比,A1T、B3T和C3T的紫外-可见光谱在约665、620、545和455 nm处出现轻微蓝移,表明ZnO NPs与TCC中的化合物之间存在相互作用。

在图6c中,O-H伸缩振动出现在3450 cm−1处,C-H伸缩振动可在2919 cm−1和2852 cm−1处观察到。1429 cm−1处的峰归属于C-H弯曲振动。837和872 cm−1处的峰属于C=C弯曲振动。FTIR光谱中的这些峰证实了纳米制剂中有机化合物的官能团的存在。此外,567 cm−1处的峰归属于Zn-O键的存在。这些证据表明纳米制剂已成功制备。25

图6d和表4显示了TGA分析结果。ZnO纳米制剂在室温至900 °C的加热过程中经历了2或3个失重步骤。第一步发生在约100 °C左右,对应于水分蒸发造成的失重。三种纳米制剂的第二步发生在200至500 °C,A1T和B3T的第三步发生在500至900 °C,而C3T在500至900 °C未观察到失重。这些步骤是样品中有机物分解的结果。23 此外,三种样品在200–500 °C区域的dTG峰位置不同,样品热活性的差异表明纳米制剂负载了不同组成的Stixis scandens提取物。根据TGA结果,可计算出A1T、B3T和C3T中有机化合物的含量分别为7.6%、5.8%和6.7%。该结果与紫外-可见方法计算的含量(表3)吻合良好。

图7展示了A1T在pH 5和pH 7.4条件下TP和TA的释放曲线。三种纳米制剂72 h后的释放百分比如表3所示。在两种pH值下,TA的释放均快于TP,酸性环境(pH 5)有利于TA和TP从纳米制剂中的释放。在比较蒜素(allicin)和叶下珠素(phyllanthin)从其Ag纳米颗粒中的释放时也观察到类似现象。51 TA在纳米制剂中的负载量更高但释放量低于TP(表3),表明TA可能比TP对纳米制剂的生物活性贡献更大。正如一篇综述文章所指出的,一些生物碱对PEDV的EC50抑制浓度分别为13.41 ± 1.13 μM、4.49 ± 0.67 μM和6.17 ± 0.50 μM。另一种生物碱高三尖杉酯碱甚至在500 nM浓度下完全抑制了PEDV感染。52 多酚如EGCG需要更高浓度才能抑制PEDV(EC50 = 83.18 μM)。53

图8 细胞毒性结果(a),未感染的Vero细胞(模拟对照)(b),Vero TCC A1T B3T C3T 31.2 3.9 15.6 3.9 15.6 — 7.8 — © 2024 作者。由英国皇家化学会出版

感染未处理PEDV的细胞(c),感染3.9 mg mL⁻¹ A1T处理PEDV的Vero细胞(d),感染7.8 mg mL⁻¹ C3T处理PEDV的Vero细胞(e)。RSC Adv., 2024, 14, 8779–8789 | 8787 在线查看文章

开放获取文章。发表于2024年3月14日。于2026年5月31日 凌晨2:41:26下载。 本文采用知识共享署名-非商业性使用3.0未本地化版本许可协议授权。

RSC Advances 表5和图8展示了细胞毒性和PEDV治疗实验的结果。C3T对Vero细胞的细胞毒性高于B3T和A1T(MNTC较低)。这可能与C3T纳米制剂中ZnO NPs的尺寸较小有关。54,55 虽然B3T和C3T在MNTC下未显示出PEDV抑制活性,但A1T纳米制剂和单独提取物(TCC)的MIC值相同,均为3.9(mg mL⁻¹)。B3T和C3T中的提取物含量可能不足以抑制PEDV。然而,在A1T中,提取物仅占纳米制剂的7.6%,却具有与100%提取物相当的抗病毒活性。这证实了纳米制剂提高了植物提取物的抗病毒活性。 在另一项研究中,据报道,紫锥菊乙醇提取物的壳聚糖-二氧化硅纳米制剂比单独提取物表现出更好的生物学效应。47

4. 结论 总之,使用Stixis scandens叶水提取物成功制备并表征了ZnO NPs。改变煅烧温度以及提取物与Zn前驱体的体积比可获得不同尺寸的ZnO-NP。TCC为Stixis scandens的乙醇提取物,其TP含量为38.51 ± 0.25 mg GAE/mg,TA含量为22.37 ± 0.41 mg AtrE/mg,将其掺入ZnO-NPs中形成A1T、B3T和C3T三种纳米制剂。这些纳米制剂含有5.8–7.6%的提取物,其中TP负载量较低但释放量较高。提取物含量最高的A1T显示出与单独提取物相当的PEDV抑制活性。尽管这些结果对于开发用于治疗PEDV的纳米制剂具有前景,但应进一步研究以阐明纳米制剂如何抑制PEDV的发展,以及提取物中的哪些化合物在抑制中起关键作用。

作者贡献 L. T. T. H.:概念构思、资金获取、调查研究、撰写初稿。T. T. T. 和 L. T. N. H.:调查研究。L. V. P.:监督、方法论、审阅与编辑。

利益冲突 无利益冲突需要声明。